can hypomethylating agents plus venetoclax replace chemotherapy induction for patients with aml?
Published 4 years ago • 379 plays • Length 7:03Download video MP4
Download video MP3
Similar videos
-
3:40
venetoclax plus hypomethylating agents leads to high response rates in older patients with aml
-
1:57
venetoclax and azacitidine for aml ineligible for standard induction
-
6:43
venetoclax and hypomethylating agents in favorable-risk aml
-
4:10
bcl-2 inhibitors with hypomethylating agents in aml
-
3:40
hypomethylating agents for aml
-
7:03
in what patients would you replace 7 3 with venetoclax-based therapies?
-
4:23
can venetoclax plus azacitidine help aml patients ineligible for intensive treatment?
-
4:03
venetoclax for aml
-
2:50
pevonedistat, venetoclax and azacitidine for older aml patients
-
7:53
considerations for treating with venetoclax in aml
-
2:49
venetoclax and azacitidine for young patients with aml
-
1:24
omniverse: safety and tolerability of oral azacitidine plus venetoclax in patients with aml
-
4:08
what do real-world data tell us about outcomes with venetoclax/hma vs 7 3 chemotherapy?
-
3:14
hypomethylating agents in mds and aml
-
2:26
magrolimab plus azacitidine in treatment-naïve aml
-
5:06
how has aml treatment in elderly people changed in 2021?
-
1:12
hma in combination with venetoclax and magrolimab in the treatment of aml
-
6:46
how can venetoclax combinations improve outcome for flt3-mutant aml?
-
6:23
venetoclax, clad/ldac and azacitdine in older aml patients